SEC Form 4 · accession 0001209191-17-041474
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Narachi
Director
Period of report
Jun 22, 2017
Accepted (ET)
Jun 22, 2017 · 7:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 22, 2017 | A | 1,875 | $0.00 | A | 3,750 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $65.66 | Jun 22, 2017 | A | 3,750 | A | — | Jun 22, 2027 | Common Stock | 3,750 | 3,750 | D |
Explanation of responses
- F1Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018.
- F2The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 22, 2018.
Remarks
Exhibit List: Exhibit 24 - Limited Power of Attorney